CytomX Therapeutics (NASDAQ: CTMX) reported FY18 EPS of ($2.03), versus ($1.16) reported last year. Revenue for the quarter came in at $59.5 million, versus $71.6 million reported last year.

Cash, cash equivalents and short-term investments totaled $436.1 million as of December 31, 2018, compared to $374.1 million as of December 31, 2017.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.